Latest Period
Q4 2025
Security Snapshot
Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) Institutional Ownership
CUSIP: 92790C104
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
229
Shares (Excl. Options)
107,824,559
Price
$31.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- VRDN on Nasdaq
- Shares outstanding
- 95,489,675
- Price per share
- $13.90
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 107,824,559
- Total reported value
- $3,355,130,541
- % of total 13F portfolios
- 0.01%
- Share change
- +12,946,317
- Value change
- +$460,108,019
- Number of holders
- 229
- Price from insider filings
- $13.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VRDN - Viridian Therapeutics, Inc.\DE - Common Stock is tracked under CUSIP 92790C104.
- 229 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 229 to 32 between Q4 2025 and Q1 2026.
- Reported value moved from $3,355,130,541 to $42,401,691.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 229 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92790C104:
Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 15% | $345,826,621 | 16,025,330 | Fairmount Funds Management LLC | 23 Oct 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.5% | $48,373,931 | 3,575,309 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 | |||
| Commodore Capital LP | 3.9% | -28% | $69,056,000 | -$23,738,000 | 3,200,000 | -26% | Commodore Capital LP | 30 Sep 2025 |
| Deep Track Capital, LP | 2.6% | $80,163,448 | 2,524,833 | Deep Track Capital, LP | 31 Dec 2025 | |||
| Kynam Capital Management, LP | 1.5% | -70% | $46,689,677 | +$46,689,677 | 1,470,541 | Kynam Capital Management, LP | 31 Dec 2025 |
As of 31 Dec 2025, 229 institutional investors reported holding 107,824,559 shares of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN). This represents 113% of the company’s total 95,489,675 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 14,384,456 | +17% | 0.02% | $447,644,271 |
| BlackRock, Inc. | 6.7% | 6,431,923 | +18% | 0% | $200,161,442 |
| VANGUARD GROUP INC | 5.9% | 5,612,144 | +30% | 0% | $174,649,921 |
| Bellevue Group AG | 4.6% | 4,358,527 | 2.6% | $135,637,360 | |
| Fairmount Funds Management LLC | 4.1% | 3,914,458 | +13% | 9.3% | $121,817,933 |
| VR ADVISER, LLC | 4.1% | 3,882,709 | 0% | 6% | $120,829,904 |
| STATE STREET CORP | 3.6% | 3,466,560 | +36% | 0% | $107,879,347 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.6% | 3,439,414 | +42% | 0.01% | $107,036,000 |
| PERCEPTIVE ADVISORS LLC | 3.2% | 3,042,703 | +108% | 1.7% | $94,688,917 |
| Deep Track Capital, LP | 2.6% | 2,524,833 | -53% | 1.8% | $78,572,803 |
| NOVO HOLDINGS A/S | 2.5% | 2,380,000 | 0% | 5.8% | $74,065,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,992,174 | +13% | 0% | $62,006,691 |
| BAKER BROS. ADVISORS LP | 2.1% | 1,971,678 | +13% | 0.36% | $61,358,619 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.1% | 1,971,411 | +76% | 0.01% | $61,350,310 |
| TANG CAPITAL MANAGEMENT LLC | 1.9% | 1,792,626 | -37% | 2.8% | $55,786,521 |
| Eversept Partners, LP | 1.9% | 1,782,235 | -7.4% | 3.1% | $55,463,153 |
| Fisher Asset Management, LLC | 1.9% | 1,780,284 | +48% | 0.02% | $55,402,437 |
| MORGAN STANLEY | 1.8% | 1,738,224 | +806% | 0% | $54,093,536 |
| Avoro Capital Advisors LLC | 1.6% | 1,500,000 | 0.46% | $46,680,000 | |
| LOOMIS SAYLES & CO L P | 1.6% | 1,481,135 | -4.5% | 0.06% | $46,092,921 |
| Kynam Capital Management, LP | 1.5% | 1,470,541 | -67% | 3% | $45,763,236 |
| Paradigm Biocapital Advisors LP | 1.5% | 1,443,102 | -45% | 1.2% | $44,909,334 |
| ALLIANCEBERNSTEIN L.P. | 1.5% | 1,414,181 | -24% | 0.01% | $44,009,313 |
| MARSHALL WACE, LLP | 1.4% | 1,375,739 | +58% | 0.04% | $42,812,998 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,264,047 | +65% | 0.01% | $39,337,143 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,168,998 | $42,401,691 | -$22,000,097 | $19.56 | 32 |
| 2025 Q4 | 107,824,559 | $3,355,130,541 | +$460,108,019 | $31.12 | 229 |
| 2025 Q3 | 93,206,736 | $2,011,267,436 | -$24,960,784 | $21.58 | 168 |
| 2025 Q2 | 94,556,649 | $1,321,909,936 | +$44,977,645 | $13.98 | 169 |
| 2025 Q1 | 91,362,677 | $1,231,598,393 | -$2,447,073 | $13.48 | 174 |
| 2024 Q4 | 91,041,740 | $1,745,285,274 | +$57,671,232 | $19.17 | 177 |
| 2024 Q3 | 86,940,196 | $1,978,662,594 | +$415,185,793 | $22.75 | 163 |
| 2024 Q2 | 69,645,524 | $906,163,827 | -$23,346,202 | $13.01 | 137 |
| 2024 Q1 | 71,003,475 | $1,243,165,734 | +$176,083,012 | $17.51 | 134 |
| 2023 Q4 | 60,143,341 | $1,309,923,497 | +$204,167,783 | $21.78 | 131 |
| 2023 Q3 | 50,192,424 | $769,944,861 | +$32,705,128 | $15.34 | 122 |
| 2023 Q2 | 47,119,787 | $1,121,040,780 | +$92,340,222 | $23.79 | 127 |
| 2023 Q1 | 43,068,809 | $1,095,674,908 | +$43,441,205 | $25.44 | 134 |
| 2022 Q4 | 41,109,026 | $1,200,793,517 | +$91,003,851 | $29.21 | 122 |
| 2022 Q3 | 37,976,766 | $778,702,810 | +$213,427,951 | $20.51 | 104 |
| 2022 Q2 | 28,321,810 | $327,687,712 | +$27,237,558 | $11.57 | 80 |
| 2022 Q1 | 24,929,839 | $460,937,688 | -$3,304,649 | $18.49 | 71 |
| 2021 Q4 | 23,259,955 | $459,848,025 | +$113,447,608 | $19.77 | 52 |
| 2021 Q3 | 13,600,109 | $223,717,000 | +$123,512,129 | $16.45 | 38 |
| 2021 Q2 | 6,003,456 | $109,804,000 | +$18,416,912 | $18.29 | 24 |
| 2021 Q1 | 5,057,213 | $84,503,000 | +$80,676,000 | $16.71 | 28 |
| 2020 Q4 | 229,000 | $3,767,000 | +$3,767,000 | $16.46 | 2 |